載入...
Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib
BACKGROUND: Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections and virus reactivations. EBV reactivation has not previously been re...
Na minha lista:
| 發表在: | BMC Hematol |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4498562/ https://ncbi.nlm.nih.gov/pubmed/26167286 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12878-015-0029-1 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|